Four‐year allograft survival in a highly sensitized combined liver–kidney transplant patient despite unsuccessful anti‐HLA antibody reduction with rituximab, splenectomy, and bortezomib. (15th May 2013)

• Record Type: Journal Article
• Authors: Koch, Martina; Gräser, Christian; Lehnhardt, Anja; Pollok, Jörg M.; Kröger, Nikolaus; Verboom, Murielle; Thaiss, Friedrich; Eiermann, Thomas; Nashan, Björn
• Is Part Of: Transplant international. Volume 26:Number 8(2013:Aug.)
• Page Start: e64
• Page End: e68
• Publication Date: 2013-05-15
• Subjects: Transplantation of organs, tissues, etc -- Periodicals; 617.95405
• DOI: 10.1111/tri.12120
• Languages: English
• ISSNs: 0934-0874

Abstract

<abstract abstract-type="main" id="tri12120-abs-0001"> <title>Summary</title> <p>Although donor‐specific lymphocytotoxic antibodies are regarded as a contraindication for kidney transplantation (KTx), the data available for liver or combined liver or kidney transplantation (cLKTx) are scarce. Here, we report a case of a highly sensitized young man receiving his sixth liver and second kidney graft. Multiple anti‐HLA antibodies were present at the time of transplantation. As a result of suspected antibody‐mediated graft damage, the patient was treated with rituximab, plasmapheresis, intravenous immunoglobulins, splenectomy, and bortezomib to decrease the antibody production. So far, patient and allograft survival has reached 4 years despite failure to achieve a permanent reduction of anti‐HLA antibodies, and particularly nondonor directed antibodies.</p> </abstract>